ESPN New York’s Ian O’Connor on last night’s game-tying homer from Alex Rodriguez:
With the ball streaking like a comet across the black Bronx night,
making Yankee Stadium quake like the old place always did, Alex Rodriguez flipped his bat, shot a look-at-me-now stare into the home
dugout, and left this baffling question in his wake: Why
did he ever feel compelled to use “boli” in the first place?
was never a slugger who needed to wage a war of back-room pharmacology.
Naturally big and fast, born with an innate ability to get the barrel
on the ball, A-Rod didn’t have to turn the game of big league baseball
into a battle of my underground chemist against yours.
Look, you can feel however you want about Alex Rodriguez and you’d be totally accurate to say that he broke the rules of baseball because he did. But if you’re going to take the “A-Rod is great and never needed steroids” line today, you probably need to walk your A-Rod “cheated the
game, cheated the fans and cheated himself” rebop from two months ago back a little bit.
Why? Because saying in March that he was a “chemically-altered fraud” whose “steroid
stain will last forever” and saying in May that “see, he never really needed steroids after all” is a tad inconsistent. PEDs either helped him or they didn’t, and you don’t get to choose which one of those things you prefer to fit the story you’re writing on any particular day. If they did helped A-Rod as much as O’Connor said they did back in March, he pretty much has to accuse A-Rod of still doing them to support his
“A-Rod is teh awesome!” story. If they didn’t, he pretty much has to admit that he was spewing baseless PED invective for the past several years.
Of course, I’m not going to hold my breath here waiting for Ian O’Connor to admit that maybe, just maybe, PEDs aren’t as bad as he usually likes to pretend they are. But I would ask that if he’s going write an otherwise fine story about an exciting ballgame he refrain from interjecting a totally beside the point and quite apparently inconsistent steroids narrative into the mix.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.